ERAS-10 / Erasca - LARVOL DELTA

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway (GlobeNewswire) - "As such, we are deprioritizing our ERAS-601 clinical trial (FLAGSHP-1) and our preclinical ERAS-5 ULK inhibitor and ERAS-10 protein degrader programs."

Pipeline update • Trial status • Oncology • Solid Tumor